Skip to main content

Table 1 Patients' features

From: "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

 

Total N. (%)

No. of patients

50

Sex

 

   Male/Female

31/19

Age, years

 

   median

63

   range

40-73

   ≥ 65 years

24 (48)

WHO Performance Status

 

   0

48 (96)

   1-2

2 (4)

Metastatic disease

 

   metachronous

15 (30)

   synchronous

35 (70)

Primary tumor

 

   colon

24 (48)

   rectum

26 (52)

Sites of metastases

 

   liver

33 (66)

   lung

10 (20)

   lymph nodes

17 (34)

   local

10 (20)

   Other

5 (10)

No. of involved sites

 

   1

32 (64)

   ≥ 2

18 (36)

Single metastatic sites

 

   liver

22 (44)

   lung

3 (6)

   lymph nodes

3 (6)

   local

4 (8)

Liver metastases

 

   single

11 (22)

   multiple

22 (44)

Previous adjuvant chemotherapy:

9 (18)

   FA/5-FU bolus

4 (8)

   Capecitabine

1 (2)

   FOLFOX4

4 (8)

Previous radiotherapy:

6 (12)

   RT alone

2 (4)

   RT+CT (5-FU c.i.)

3 (6)

   RT+CT (XELOX)

1 (2)

  1. Abbreviation: WHO, World Health Organization; c.i., continous infusion.